{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:20:44Z","timestamp":1763036444074},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T00:00:00Z","timestamp":1261008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00393-009-0515-6","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T10:58:11Z","timestamp":1260874691000},"page":"19-24","source":"Crossref","is-referenced-by-count":11,"title":["Aktuelle therapeutische Optionen bei Sj\u00f6gren-Syndrom"],"prefix":"10.1007","volume":"69","author":[{"given":"A.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,17]]},"reference":[{"key":"515_CR1","doi-asserted-by":"crossref","unstructured":"Ami S, Wolff A (2009) Implant-supported electrostimulating device to treat xerostomia: A preliminary study. Clin Implant Dent Relat Res [Epub ahead of print]","DOI":"10.1111\/j.1708-8208.2009.00180.x"},{"key":"515_CR2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0002-9394(00)00620-6","volume":"131","author":"Balaram","year":"2001","unstructured":"Balaram M, Schaumberg DA, Dana MR (2001) Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 131:30\u201336","journal-title":"Am J Ophthalmol"},{"key":"515_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00417-004-0955-2","volume":"243","author":"Coassin","year":"2005","unstructured":"Coassin M, Lambiase A, Costa N et al (2005) Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol 243:151\u2013155","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"515_CR4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/BOR.0b013e32832a0760","volume":"21","author":"Daridon","year":"2009","unstructured":"Daridon C, Burmester GR, D\u00f6rner T (2009) Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol 21:205\u2013210","journal-title":"Curr Opin Rheumatol"},{"key":"515_CR5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"Dass","year":"2008","unstructured":"Dass S, Bowman SJ, Vital EM et al (2008) Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67:1541\u20131544","journal-title":"Ann Rheum Dis"},{"key":"515_CR6","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1517\/14712598.8.11.1805","volume":"8","author":"Ding","year":"2008","unstructured":"Ding C (2008) Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 8:1805\u20131814","journal-title":"Expert Opin Biol Ther"},{"key":"515_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00393-007-0231-z","volume":"66","author":"Feist","year":"2007","unstructured":"Feist E, D\u00f6rner T, Hansen A (2007) Indikation und Option neuer immunmodulatorischer Therapien beim Sj\u00f6gren-Syndrom. Z Rheumatol 66:679\u2013685","journal-title":"Z Rheumatol"},{"key":"515_CR8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.1780270415","volume":"27","author":"Fox","year":"1984","unstructured":"Fox RI, Chan R, Michelson JB et al (1984) Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 27:459\u2013461","journal-title":"Arthritis Rheum"},{"key":"515_CR9","first-page":"1216","volume":"9","author":"Gatto","year":"2008","unstructured":"Gatto B (2008) Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 9:1216\u20131227","journal-title":"Curr Opin Investig Drugs"},{"key":"515_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","volume":"109","author":"Groom","year":"2002","unstructured":"Groom J, Kalled SL, Cutler AH et al (2002) Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren\u2019s syndrome. J Clin Invest 109:59\u201368","journal-title":"J Clin Invest"},{"key":"515_CR11","first-page":"57","volume":"3","author":"Gumus","year":"2009","unstructured":"Gumus K, Cavanagh DH (2009) The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clin Ophthalmol 3:57\u201367 [Epub 2009 Jun 2]","journal-title":"Clin Ophthalmol"},{"key":"515_CR12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ncprheum0620","volume":"3","author":"Hansen","year":"2007","unstructured":"Hansen A, Lipsky PE, D\u00f6rner T (2007) B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 3:561\u2013569","journal-title":"Nat Clin Pract Rheumatol"},{"key":"515_CR13","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/ar2210","volume":"9","author":"Hansen","year":"2007","unstructured":"Hansen A, Lipsky PE, D\u00f6rner T (2007) B cells in Sj\u00f6gren\u2019s syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 9:R218","journal-title":"Arthritis Res Ther"},{"key":"515_CR14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.bor.0000172801.56744.c3","volume":"17","author":"Hansen","year":"2005","unstructured":"Hansen A, Lipsky PE, Dorner T (2005) Immunopathogenesis of primary Sj\u00f6gren\u2019s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17:558\u2013565","journal-title":"Curr Opin Rheumatol"},{"key":"515_CR15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly Pan (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5:341\u2013353","journal-title":"Lancet Oncol"},{"key":"515_CR16","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","volume":"164","author":"Kassan","year":"2004","unstructured":"Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sj\u00f6gren syndrome. Arch Intern Med 164:1275\u20131284","journal-title":"Arch Intern Med"},{"key":"515_CR17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14712590903018837","volume":"9","author":"Kausar","year":"2009","unstructured":"Kausar F, Mustafa K, Sweis G et al (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 9:889\u2013895","journal-title":"Expert Opin Biol Ther"},{"key":"515_CR18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3949\/ccjm.64.10.523","volume":"64","author":"Linardaki","year":"1997","unstructured":"Linardaki G, Moutsopoulos HM (1997) The uncertain role of immunosuppressive agents in Sj\u00f6gren\u2019s syndrome. Cleve Clin J Med 64:523\u2013526","journal-title":"Cleve Clin J Med"},{"key":"515_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0961203396005001071","volume":"5","author":"Manoussakis","year":"1996","unstructured":"Manoussakis MN, Moutsopoulos HM (1996) Antimalarials in Sj\u00f6gren\u2019s syndrome \u2013 the Greek experience. Lupus 5 (Suppl 1):28\u201330","journal-title":"Lupus"},{"key":"515_CR20","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S et al (2004) Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS). Arthritis Rheum 50:1270\u20131276","journal-title":"Arthritis Rheum"},{"key":"515_CR21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","volume":"68","author":"Meijer","year":"2009","unstructured":"Meijer JM, Pijpe J, Vissink A et al (2009) Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 68:284\u2013285","journal-title":"Ann Rheum Dis"},{"key":"515_CR22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","volume":"46","author":"Petrone","year":"2002","unstructured":"Petrone D, Condemi JJ, Fife R et al (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sj\u00f6gren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46:748\u2013754","journal-title":"Arthritis Rheum"},{"key":"515_CR23","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"Pijpe","year":"2005","unstructured":"Pijpe J, Imhoff GW van, Spijkervet FK et al (2005) Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study. Arthritis Rheum 52:2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"515_CR24","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","volume":"60","author":"Pijpe","year":"2009","unstructured":"Pijpe J, Meijer JM, Bootsma H et al (2009) Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 60:3251\u20133256","journal-title":"Arthritis Rheum"},{"key":"515_CR25","first-page":"896","volume":"25","author":"Price","year":"1998","unstructured":"Price EJ, Rigby SP, Clancy U et al (1998) A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren\u2019s syndrome. J Rheumatol 25:896\u2013899","journal-title":"J Rheumatol"},{"key":"515_CR26","first-page":"1338","volume":"145","author":"Robinson","year":"2009","unstructured":"Robinson JK (2009) Linking publication about efalizumab effectiveness with safety concerns. Arch Dermatol 145:1338","journal-title":"Arch Dermatol"},{"key":"515_CR27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"Sall","year":"2000","unstructured":"Sall K, Stevenson \u00d6D, Mundorf TK et al (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107:631\u2013639","journal-title":"Ophthalmology"},{"key":"515_CR28","doi-asserted-by":"crossref","unstructured":"Seror R, Ravaud P, Bowman S et al (2009) EULAR Sjogren\u2019s Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjogren\u2019s syndrome. Ann Rheum Dis [Epub ahead of print]","DOI":"10.1136\/ard.2009.110619"},{"key":"515_CR29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L et al (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 66:351\u2013357","journal-title":"Ann Rheum Dis"},{"key":"515_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/jir.1998.18.255","volume":"18","author":"Shiozawa","year":"1998","unstructured":"Shiozawa S, Tanaka Y, Shiozawa K (1998) Single-blinded controlled trial of low-dose oral IFN-\u03b1 for the treatment of xerostomia in patients with Sj\u00f6gren\u2019s syndrome. J Interferon Cytokine Res 18:255\u2013262","journal-title":"J Interferon Cytokine Res"},{"key":"515_CR31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","volume":"49","author":"Somer","year":"2003","unstructured":"Somer BG, Tsai DE, Downs L et al (2003) Improvement in Sj\u00f6gren\u2019s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49:394\u2013398","journal-title":"Arthritis Rheum"},{"key":"515_CR32","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/rheumatology\/38.9.814","volume":"38","author":"Steinfeld","year":"1999","unstructured":"Steinfeld SD, Demols P, Van Vooren JP et al (1999) Zidovudine in primary Sj\u00f6gren\u2019s syndrome. Rheumatol Oxford 38:814\u2013817","journal-title":"Rheumatol Oxford"},{"key":"515_CR33","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"Steinfeld","year":"2006","unstructured":"Steinfeld SD, Tant L, Burmester GR et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren\u2019s syndrome: an open-label phase I\/II study. Arthritis Res Ther 8:R129","journal-title":"Arthritis Res Ther"},{"key":"515_CR34","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"Theander","year":"2006","unstructured":"Theander E, Henriksson G, Ljungberg O et al (2006) Lymphoma and other malignancies in primary Sj\u00f6gren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796\u2013803","journal-title":"Ann Rheum Dis"},{"key":"515_CR35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"Vivino","year":"1999","unstructured":"Vivino FB, Al-Hashimi I, Khan Z et al (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye Symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92\u201301 Study Group. Arch Intern Med 159:174\u2013181","journal-title":"Arch Intern Med"},{"key":"515_CR36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"515_CR37","first-page":"96","volume":"31","author":"Zandbelt","year":"2004","unstructured":"Zandbelt MM, Wilde P de, Damme P van et al (2004) Etanercept in the treatment of patients with primary Sj\u00f6gren\u2019s syndrome: a pilot study. J Rheumatol 31:96\u2013101","journal-title":"J Rheumatol"},{"key":"515_CR38","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"Zintsaras","year":"2005","unstructured":"Zintsaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337\u20132344","journal-title":"Arch Intern Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0515-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0515-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:35:59Z","timestamp":1559061359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0515-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0515-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,17]]}}}